Characteristics of thoracic malignancies that occur after solid-organ transplantation

Journal of Thoracic Oncology

Volumn 5, Issue 11, 2010, Pages 1789-1795

  Génébès, Caroline ^a,b   Brouchet, Laurent ^b   Kamar, Nassim ^c   Lepage, Benoit ^d   Prévot, Grégoire ^a   Rostaing, Lionel ^d,e   Didier, Alain ^b   Mazières, Julien ^b  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b SERVICE DE PNEUMOLOGIE   (France)

^c CHU RANGUEIL   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e CHU PURPAN   (France)

Author keywords

Immunosuppression; Lung cancer; Prognosis; Transplantation

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; DEMOGRAPHY; FEMALE; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG CANCER; LUNG TRANSPLANTATION; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; SMOKING; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME;

EID: 78149419699     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181f19226     Document Type: Article

References (46)

1. Penn I, Branson ME. Cancer after cyclosporin therapy. Transplant Proc 1988;20:885-892.
2. Penn I. Cancers complicating organ transplantation. N Engl J Med 1990;323:1767-1768.
3. Couetil JP, McGoldrick JP, Wallwork J. Malignant tumors after heart transplantation. J Heart Transplant 1990;9:622-626.
4. Sheil AG, Disney AP, Mathew TH, et al. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 1993;25:1383-1384.
5. Fleming RH, Jennison SH, Naunheim KS. Primary bronchogenic carcinoma in the heart transplant recipient. Ann Thorac Surg 1994;57:1300-1301.
6. Pham SM, Kormos RL, Landreneau RJ, et al. Solid tumors after heart transplantation: lethality of lung cancer. Ann Thorac Surg 1995;60: 1623-1626.
7. Delcambre F, Pruvot FR, Ramon P, et al. Primary bronchogenic carcinoma in transplant recipients. Transplant Proc 1996;28:2884-2885.
8. Penn I. Overview of the problem of cancer in organ transplant recipients. Ann Transplant 1997;2:5-6.
9. Taniguchi S, Cooper DK, Chaffin JS, et al. Primary bronchogenic carcinoma in recipients of heart transplants. Transpl Int 1997;10:312-316.
10. Curtil A, Robin J, Tronc F, et al. Malignant neoplasms following cardiac transplantation. Eur J Cardiothorac Surg 1997;12:101-106.
11. Choi YH, Leung AN, Miro S, et al. Primary bronchogenic carcinoma after heart or lung transplantation: radiologic and clinical findings. J Thorac Imaging 2000;15:36-40.
12. Collins J, Kazerooni EA, Lacomis J, et al. Bronchogenic carcinoma after lung transplantation: frequency, clinical characteristics, and imaging findings. Radiology 2002;224:131-138.
13. Anyanwu AC, Townsend ER, Banner NR, et al. Primary lung carcinoma after heart or lung transplantation: management and outcome. J Thorac Cardiovasc Surg 2002;124:1190-1197.
14. Potaris K, Radovancevic B, Thomas CD, et al. Lung cancer after heart transplantation: a 17-year experience. Ann Thorac Surg 2005;79:980-983.
15. Roithmaier S, Haydon AM, Loi S, et al. Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience. J Heart Lung Transplant 2007;26:845-849.
16. Vegso G, Toth M, Hidvegi M, et al. Malignancies after renal transplantation during 33 years at a single center. Pathol Oncol Res 2007;13:63-69.
17. Minai OA, Shah S, Mazzone P. Bronchogenic carcinoma after lung transplantation: characteristics and outcomes. J Thorac Oncol 2008;3: 1404-1409.
18. Zafar SY, Howell DN, Gockerman JP. Malignancy after solid organ transplantation: an overview. Oncologist 2008;13:769-778.
19. Delgado M, Fernandez R, Paradela M, et al. Development of neoplasms during lung transplantation follow-up. Transplant Proc 2008;40:3094-3096.
20. Stratta P, Morellini V, Musetti C, et al. Malignancy after kidney transplantation: results of 400 patients from a single center. Clin Transpl 2008;22:424-427.
21. Kellerman L, Neugut A, Burke B, et al. Comparison of the incidence of de novo solid malignancies after heart transplantation to that in the general population. Am J Cardiol 2009;103:562-566.
22. Bruschi G, Conforti S, Torre M, et al. Long-term results of lung cancer after heart transplantation: single center 20-year experience. Lung Cancer 2009;63:146-150.
23. Miao Y, Everly JJ, Gross TG, et al. De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation 2009;87:1347-1359.
24. Padilla J, Ceron J, Penalver JC, et al. Bronchogenic carcinoma in patients undergoing solid organ transplant. The role of surgery. Cir Esp 2009;86:101-104.
25. Mohammadi S, Bonnet N, Leprince P, et al. Long-term survival of heart transplant recipients with lung cancer: the role of chest computedtomography screening. Thorac Cardiovasc Surg 2007;55:438-441.
26. Shoji F, Kawano D, Ikegami T, et al. Surgical resection of pulmonary malignant tumors after living donor liver transplantation. Ann Thorac Surg 2009;88:206-211.
27. Penn I. Incidence and treatment of neoplasia after transplantation. J Heart Lung Transplant 1993;12:S328-S336.
28. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clinical Transpl 1998:147-158.
29. Penn I. Post-transplant malignancies. Transplant Proc 1999;31:1260-1262.
30. Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer 2009;125:1747-1754.
31. de Perrot M, Wigle DA, Pierre AF, et al. Bronchogenic carcinoma after solid organ transplantation. Ann Thorac Surg 2003;75:367-371.
32. Ahmed Z, Marshall MB, Kucharczuk JC, et al. Lung cancer in Transplant recipients: a single-institution experience. Arch Surg 2004;139: 902-906.
33. Minai OA, Shah S, Mazzone P, et al. Bronchogenic carcinoma after lung transplantation: characteristics and outcomes. J Thorac Oncol 2008;3: 753-760.
34. Mathew J, Kratzke RA. Lung cancer and lung transplantation: a review. J Thorac Oncol 2009;4:753-760.
35. Kreimer AR, Clifford GM, Boyle P, et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:467-475.
36. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
37. Jemal A, Murray T, Ward E, et al. Cancer statistics 2005. CA Cancer J Clin 2005;55:10-30.
38. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-1717.
39. Webster AC, Lee VW, Chapman JR, et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006;81:1234-1248.
40. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-918.
41. Hudes G, Carducci M, Tomczak P, et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol 2006;24:Abstract LBA4.
42. Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23:5314-5322.
43. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80:883-889.
44. Guba M, Graeb C, Jauch KW, et al. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 2004;77:1777-1782.
45. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after earlyciclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006;17:581-589.
46. Boratynska M, Watorek E, Smolska D, et al. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies. Transplant Proc 2007;39:2736-2739.